Total pharma industry M&A deals in April 2019 worth $3.33bn were announced in the US, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 5.2% over the previous month and a drop of 75.9% when compared with the last 12-month average of $13.84bn.
The US held an 81.2% share of the global pharma industry M&A deal value that totalled $4.1bn in April 2019.
In terms of deal activity, the US recorded 20 deals during April 2019, marking an increase of 33.3% over the previous month and a drop of 5.3% over the 12-month average.
The US pharma industry M&A deals in April 2019: Top deals
The top five pharma industry M&A deals accounted for 99.5% of the overall value during April 2019.
The combined value of the top five pharma industry M&A deals stood at $3.31bn, against the overall value of $3.33bn recorded for the month. The top announced pharma industry M&A deal tracked by GlobalData in April 2019 was Novartis ‘ $1.58bn acquisition of IFM Tre .
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.